We're developing new minimal residual disease tests, and that helps to identify which patients will benefit from allogeneic ...

Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a2-year overall survival rate of 90% vs ...

Sellas will participate Wednesday in TD Cowen’s Oncology Innovation Summit, marking the final major conference appearance ...

Researchers have tested a gene-edited stem cell transplant designed to shield healthy blood-forming cells from powerful ...

I think probably the best one is the urban patient who has access to an academic medical center that is running clinical ...

Nidahl Hamdan said signing up to the register "could save someone's life" A young woman whose mother has been diagnosed with ...

"I had never even heard of this diagnosis, and judging from my early symptoms, I never would have thought I had a serious ...